Abstract
In oncology trials, PROM endpoints provide a valuable complement to endpoints such as tumour response and are central to the patient’s understanding of treatment benefits. The burden of regular PROM completion is poorly understood, yet invaluable in informing PROM selection and scheduling strategies. We examine completion times, often seen as an indicator of burden, for commonly used PROMs in oncology to better understand how measure selection translates to patient time investment in clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
